NCT06253663View on ClinicalTrials.gov

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Relapsed/Refractory Mantle Cell LymphomaRelapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions
DRUG

KTE-X19

A single infusion of chimeric antigen receptor (CAR) T cells

DRUG

Cyclophosphamide

Administered intravenously

DRUG

Fludarabine

Administered intravenously

Trial Locations (9)

260-8677

Chiba University Hospital, Chiba

812-8582

Kyushu University Hospital, Fukuoka

060-8648,

Hokkaido University Hospital, Hokkaido

606-8507

Kyoto University Hospital, Kyoto

980-8574

Tohoku University Hospital, Miyagi

700-8558

Okayama University Hospital, Okayama

104-0045

National Cancer Center Hospital, Tokyo

113-8431

Juntendo University Hospital, Tokyo

113-8677

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo

All Listed Sponsors
lead

Kite, A Gilead Company

INDUSTRY

NCT06253663 - Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter